Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
14.19
-1.11 (-7.25%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
533.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| C4 Therapeutics | 35.04M |
| Adlai Nortye | 19.54M |
| Evommune | 10.00M |
| Prime Medicine | 4.07M |
| Ovid Therapeutics | 1.58M |
| Artiva Biotherapeutics | 251.00K |
CTNM News
- 15 days ago - Contineum initiated with an Outperform at LifeSci Capital - TheFly
- 16 days ago - Contineum reports Q2 EPS (40c), consensus (45c) - TheFly
- 16 days ago - Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 16 days ago - Contineum Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Contineum Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry - TheFly
- 6 weeks ago - Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - Business Wire
- 2 months ago - Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts